BMP2 and IL-1Ra Viral Vectors for Bone Regeneration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for large segmental bone defects, such as autologous bone grafts and allografts, are limited by supply issues, donor site morbidity, and lack of osteoinductive properties, while surgical methods like distraction osteogenesis are complex and time-consuming, and all suffer from complications like infection and poor integration.
Innovation Solution
The use of viral vectors expressing both BMP2 and IL-1Ra polypeptides to promote bone growth and regeneration, reducing bone loss and enhancing healing without significant inflammatory immune response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If autologous bone grafts are used to treat large segmental bone defects, then bone regeneration can be achieved, but donor site morbidity and limited supply occur
Solution Approach 1:
The patent extracts the osteoinductive properties from autologous bone grafts by isolating and expressing BMP-2 protein through viral vectors. This separates the regenerative function from the donor site, eliminating donor site morbidity while maintaining bone regeneration capability through recombinant protein expression in the defect site.
Solution Approach 2:
The patent creates a functional copy of the osteoinductive properties using recombinant BMP-2 protein expressed via viral vectors. Instead of using actual autologous bone, the patent copies the essential regenerative signal (BMP-2) and delivers it through viral vectors, achieving the same biological effect without the drawbacks of donor site surgery.
2Quantity of substance
If allografts are used to treat bone defects, then unlimited supply is available, but osteoinductive properties are lost due to processing
Solution Approach 1:
The patent changes the form of bone regeneration from processed allograft material to recombinant protein expression. By using viral vectors to express BMP-2 protein, the patent maintains unlimited supply (protein can be manufactured as needed) while preserving full osteoinductive properties, as the protein is freshly synthesized and not processed from donor bone.
3Reliability
If distraction osteogenesis is used to treat large segmental defects, then bone growth can be stimulated, but the procedure is complex and time-consuming
Solution Approach 1:
The patent replaces the mechanical distraction osteogenesis system with a biological solution using viral vectors expressing BMP-2. Instead of using external fixation devices and mechanical distraction to stimulate bone growth, the patent uses viral vectors to deliver osteoinductive protein, simplifying the treatment to a single injection procedure that directly promotes bone formation.
4Reliability
If high doses of BMP polypeptide are administered to promote bone growth, then bone regeneration is enhanced, but inflammatory immune response increases
Solution Approach 1:
The patent uses viral vectors as intermediaries to deliver BMP-2 protein. The viral vector system controls the release and localization of BMP-2, enabling effective bone regeneration at low doses while preventing systemic inflammatory responses. The vector acts as a controlled delivery mechanism that targets the protein to the defect site without triggering widespread immune activation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach facilitates high-quality bone formation via endochondral ossification, reducing bone loss and promoting regeneration without adverse immune reactions, using low doses and minimizing treatment frequency.
Implementation Method 1
viral vectors designed to express (a) a nucleotide sequence encoding a bone morphogenetic protein (BMP) polypeptide
Implementation Method 2
BMP polypeptide can promote bone growth and/or bone regeneration within the mammal
Implementation Method 3
polypeptide that can inhibit an interleukin-1 (IL-1) polypeptide (e.g., an interleukin-1 receptor antagonist (IL-1Ra) polypeptide)
Implementation Method 4
This approach facilitates high-quality bone formation via endochondral ossification
Data Source
AI summary
This document provides methods and materials involved in promoting bone growth. For example, this document provides vectors designed to express (a) a nucleotide sequence encoding a bone morphogenetic protein 2 (BMP2) polypeptide and/or (b) a nucleotide sequence encoding an interleukin-1 receptor antagonist (IL-1Ra) polypeptide for promoting bone growth. In some cases, one or more vectors provided herein can be administered to a mammal (e.g., a human) having a disease, disorder, or condition associated with bone loss to treat the mammal. For example, a population of a single vector provided herein can be used to increase expression of a BMP2 polypeptide and an IL-1Ra polypeptide by cells within a mammal (e.g., a human) having a disease, disorder, or condition associated with bone loss to promote bone growth within the mammal.